Abstract

The aim of this study was to evaluate the diagnostic value of serumCK20 mRNA as a biomarker for colorectal cancer diagnosis by meta-analysis.Clinical studies related to serum CK20 mRNA expression for colorectal cancer diagnosis were searched in the databases of Pubmed, Cochrane Library, Embase, ISI Web of Knowledge, CNKI and Wanfang. The number of true positive (tp), false positive (fp), false negative (fn) and true negative (tn) of the original included publications were extracted by two reviewers independently. The diagnostic sensitivity, specificity, positive likely hood ratio (+LR), negative likelyhood ratio (-LR), diagnostic odds ratio (DOR) and area under the symmetric ROC curve (AUC) were pooled by random or fixed effect method according to the statistical heterogeneity among the studies.After screening the databases, nineteen publications met the inclusion criteria and were finally included in this meta-analysis. The diagnostic sensitivity and specificity were pooled by random effect model(I2>50%). The pooled diagnostic sensitivity and specificity of CK20 mRNA in serum as biomarker for colorectal cancer were 0.49 (95% CI:0.46 to 0.51) and 0.94 (95%CI:0.92-0.96) respectively. The pooled +LR and −LR were 10.90 (95%CI:5.78 to 20.55) and 0.51 (95%CI:0.45 to 0.57) respectively by random-effect method. The pooled DOR was 22.31 with the 95% CI of 11.65 to 42.71. The pooled area under the ROC curve (AUC) was 0.72for CK20 mRNA in serum as a biomarker for colorectal cancer diagnosis. Conclusion Serum CK20 mRNA expression was significantly elevated in colorectal cancer patients which could be a promising serum biomarker for colorectal cancer diagnosis with high specificity.

Highlights

  • Colorectal cancer accounting for 1,000,000 new cases peryear is one of the most diagnosed malignant carcinoma world-wide [1]

  • Serum Cytokertation 20 (CK20) mRNA was examined by real-time quantitative PCR (RT-qPCR) and FQ-PCR assay in 15 and 4 studies respectively

  • Population based colorectal cancer screening for high risk patients is a key method for identifying early stage patients and improving the prognosis

Read more

Summary

Introduction

Colorectal cancer accounting for 1,000,000 new cases peryear is one of the most diagnosed malignant carcinoma world-wide [1]. Its incidence ranks the third just behind lung cancer and breast cancer. In China, colorectal cancer is one of the leading causes of cancer related death with an incidence rate of 13.6/100,000 for males and 9.2/100,000 for females which is still on the rise [2]. The prognosis of colorectal cancer is relatively good for early stage patients. The long-term survival rate is very low for advanced metastatic disease. Early diagnosis is important for improving the survival of patients with colorectal cancer. Serum biomarkers for colorectal cancer screening or diagnosis is generally used clinically such as CEA, CA199 and et al [3, 4].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call